Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Keith Stewart

Showing results (171-180 of 208) with videos related to

Pageof 21
Sort By:
Blood|December 17, 2009
Lenalidomide plus dexamethasone versus thalidomide plus dexamethasone in newly diagnosed multiple myeloma: a comparative analysis of 411 patientsFrancesca Gay, Suzanne R Hayman, Martha Q Lacy, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|April 15, 2021
Germline Cancer Susceptibility Gene Testing in Unselected Patients With Colorectal Adenocarcinoma: A Multicenter Prospective StudyPedro L S Uson, Douglas Riegert-Johnson, Lisa Boardman, et al.
Blood|May 5, 2012
An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myelomaRavi Vij, Michael Wang, Jonathan L Kaufman, et al.
Blood Cancer Journal|August 1, 2018
Phase 1/2 trial of ixazomib, cyclophosphamide and dexamethasone in patients with previously untreated symptomatic multiple myelomaShaji K Kumar, Francis K Buadi, Betsy LaPlant, et al.
Mayo Clinic Proceedings|December 4, 2009
Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelinesShaji K Kumar, Joseph R Mikhael, Francis K Buadi, et al.
Blood|January 29, 2015
Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group reportAntonio Palumbo, Sara Bringhen, Maria-Victoria Mateos, et al.
Leukemia|October 14, 2024
Functional variant rs9344 at 11q13.3 regulates CCND1 expression in multiple myeloma with t(11;14)Hongwei Tang, Huihuang Yan, Suganti Shivaram, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 6, 2022
Ciltacabtagene Autoleucel, an Anti-B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-UpThomas Martin, Saad Z Usmani, Jesus G Berdeja, et al.
Blood Cancer Journal|May 13, 2020
"Direct to Drug" screening as a precision medicine tool in multiple myelomaCecilia Bonolo de Campos, Nathalie Meurice, Joachim L Petit, et al.
Blood|October 6, 2016
Randomized phase 2 trial of ixazomib and dexamethasone in relapsed multiple myeloma not refractory to bortezomibShaji K Kumar, Betsy R LaPlant, Craig B Reeder, et al.
Pageof 21

Showing results (171-180 of 208) with videos related to

Sort By:
Pageof 21
Blood|December 17, 2009
Lenalidomide plus dexamethasone versus thalidomide plus dexamethasone in newly diagnosed multiple myeloma: a comparative analysis of 411 patientsFrancesca Gay, Suzanne R Hayman, Martha Q Lacy, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|April 15, 2021
Germline Cancer Susceptibility Gene Testing in Unselected Patients With Colorectal Adenocarcinoma: A Multicenter Prospective StudyPedro L S Uson, Douglas Riegert-Johnson, Lisa Boardman, et al.
Blood|May 5, 2012
An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myelomaRavi Vij, Michael Wang, Jonathan L Kaufman, et al.
Blood Cancer Journal|August 1, 2018
Phase 1/2 trial of ixazomib, cyclophosphamide and dexamethasone in patients with previously untreated symptomatic multiple myelomaShaji K Kumar, Francis K Buadi, Betsy LaPlant, et al.
Mayo Clinic Proceedings|December 4, 2009
Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelinesShaji K Kumar, Joseph R Mikhael, Francis K Buadi, et al.
Blood|January 29, 2015
Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group reportAntonio Palumbo, Sara Bringhen, Maria-Victoria Mateos, et al.
Leukemia|October 14, 2024
Functional variant rs9344 at 11q13.3 regulates CCND1 expression in multiple myeloma with t(11;14)Hongwei Tang, Huihuang Yan, Suganti Shivaram, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 6, 2022
Ciltacabtagene Autoleucel, an Anti-B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-UpThomas Martin, Saad Z Usmani, Jesus G Berdeja, et al.
Blood Cancer Journal|May 13, 2020
"Direct to Drug" screening as a precision medicine tool in multiple myelomaCecilia Bonolo de Campos, Nathalie Meurice, Joachim L Petit, et al.
Blood|October 6, 2016
Randomized phase 2 trial of ixazomib and dexamethasone in relapsed multiple myeloma not refractory to bortezomibShaji K Kumar, Betsy R LaPlant, Craig B Reeder, et al.
Pageof 21